$EW Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.42 down -26.32% YoY
• Reported revenue of $1.74B up 13.63% YoY
• Edwards Lifesciences projects 2026 full-year sales growth of 10% to 11% and reaffirms adjusted EPS guidance of $2.95 to $3.05, while expecting Q3 2026 sales between $1.63 and $1.71 billion.